PAR - 416 mill MC
RAC - 423 mill MC
OPT - 456 mill MC
NEU - 260 mill MC
IXC - 49 mill MC
Even if it got to NEU say, thats 5 x from here or $3.50 share price. Get real punters, this is the biggest gift on the ASX. Wait in 2 years time when we will say to ourselves, I cant believe how obvious this was, wish I bought more.
Dr Duthy also noted that comparable companies on the ASX which are either repurposing approved therapies, developing orphan drugs, or developing ophthalmology therapies, such asParadigm Biopharmaceuticals (ASX: PAR),Opthea (ASX: OPT),Race Oncology (ASX: RAC)orNeuren Pharmaceuticals (ASX: NEU), are priced significantly higher despite similar stages of development.
Patience people patience
- Forums
- ASX - By Stock
- IXC
- Ann: Invex Granted Key European Patent for Exenatide
IXC
invex therapeutics ltd
Add to My Watchlist
18.2%
!
13.0¢

Ann: Invex Granted Key European Patent for Exenatide, page-45
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
13.0¢ |
Change
0.020(18.2%) |
Mkt cap ! $9.77M |
Open | High | Low | Value | Volume |
11.0¢ | 13.0¢ | 11.0¢ | $3.651K | 28.89K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 17727 | 10.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
13.0¢ | 50146 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 17727 | 0.105 |
1 | 12000 | 0.100 |
1 | 50000 | 0.095 |
1 | 100000 | 0.091 |
1 | 50000 | 0.087 |
Price($) | Vol. | No. |
---|---|---|
0.130 | 50146 | 3 |
0.145 | 2000 | 1 |
0.150 | 713 | 1 |
0.160 | 8998 | 1 |
0.200 | 172823 | 1 |
Last trade - 10.45am 17/09/2025 (20 minute delay) ? |
Featured News
IXC (ASX) Chart |